Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SJX-653 in postmenopausal women with vasomotor symptoms
2019-002281-12Phase 2Unknown
- Sponsor
- Sojournix
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in menopause comparing SJX-653 with Placebo (2 arms). Primary endpoint: Change in frequency of moderate to severe vasomotor symptoms at Week 4. Status: unknown.
02
Drugs
SJX-653
03
Conditions
menopause
Beyond the preview
Go deeper on 2019-002281-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002281-12.